4,386 Shares in Edwards Lifesciences Co. (NYSE:EW) Acquired by SVB Wealth LLC

SVB Wealth LLC purchased a new position in Edwards Lifesciences Co. (NYSE:EW - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 4,386 shares of the medical research company's stock, valued at approximately $325,000.

Several other large investors also recently added to or reduced their stakes in EW. FSA Wealth Management LLC bought a new stake in Edwards Lifesciences during the third quarter valued at $30,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in Edwards Lifesciences during the fourth quarter valued at $30,000. Prospera Private Wealth LLC bought a new stake in Edwards Lifesciences during the third quarter valued at $32,000. Avior Wealth Management LLC boosted its stake in Edwards Lifesciences by 138.7% during the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company's stock valued at $35,000 after buying an additional 308 shares during the period. Finally, Roble Belko & Company Inc bought a new stake in Edwards Lifesciences during the fourth quarter valued at $46,000. Institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Trading Down 2.0 %

Shares of NYSE EW traded down $1.44 during trading hours on Friday, hitting $70.36. The company's stock had a trading volume of 5,207,628 shares, compared to its average volume of 4,502,576. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The stock has a market cap of $41.37 billion, a price-to-earnings ratio of 10.10, a P/E/G ratio of 4.82 and a beta of 1.12. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The business has a 50-day simple moving average of $72.26 and a 200-day simple moving average of $70.38.

Remove Ads

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. On average, analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other news, Director Steven R. Loranger sold 5,739 shares of the business's stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $76.42, for a total value of $438,574.38. Following the sale, the director now directly owns 60,372 shares of the company's stock, valued at $4,613,628.24. The trade was a 8.68 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Scott B. Ullem sold 11,250 shares of the business's stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $75.76, for a total value of $852,300.00. Following the completion of the sale, the chief financial officer now directly owns 30,561 shares in the company, valued at approximately $2,315,301.36. This represents a 26.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 37,739 shares of company stock valued at $2,799,104. 1.29% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on EW shares. Wolfe Research downgraded Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a research report on Wednesday, February 12th. Canaccord Genuity Group raised their price target on Edwards Lifesciences from $68.00 to $71.00 and gave the company a "hold" rating in a research report on Thursday, February 13th. Barclays raised their price target on Edwards Lifesciences from $88.00 to $90.00 and gave the company an "overweight" rating in a research report on Thursday, February 13th. Morgan Stanley raised their price target on Edwards Lifesciences from $70.00 to $75.00 and gave the company an "equal weight" rating in a research report on Wednesday, February 12th. Finally, Royal Bank of Canada restated an "outperform" rating and set a $85.00 price target on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $79.95.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.